BioAge reports Phase 1 data for BGE-102, showing 85% hsCRP reduction

• BioAge reported positive Phase 1 results for BGE-102, an oral NLRP3 inhibitor, showing strong reductions in inflammation markers in participants with obesity and elevated baseline inflammation.
• Data released included a newly disclosed 60 mg once-daily cohort, with outcomes described as comparable to previously reported results from a higher-dose group.
• BGE-102 was described as well tolerated across evaluated doses, supporting continued investment to advance the program.
• BioAge plans to start a Phase 2 dose-ranging cardiovascular risk proof-of-concept trial in first half of 2026, with results expected in second half of 2026.
• Company also plans a Phase 1b/2a proof-of-concept trial in diabetic macular edema in mid-2026, with results expected mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604210700PRIMZONEFULLFEED9693510) on April 21, 2026, and is solely responsible for the information contained therein.